The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.
You might also be interested in reading Circle debuts Arc blockchain which Jeremy Allaire calls ‘more consequential’ than USDC.
